Lenvatinib, a thyroid cancer drug meets primary endpoint in phase 3 study
Eisai has announced that the phase 3 SELECT trial ( Study 303 ) of investigational agent Lenvatinib met its primary endpoint. Compared to placebo, Lenvatinib showed a highly statistically significant ...
read article